The present study will include a population of patients with established ATTR CM. research hub

Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM).

This study is looking at a new medicine called coramitug for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR CM). Researchers want to see if it helps improve how far people can walk and other heart health markers over about a year.